Mr. Ron Nagar reports

TEMPRAMED ANNOUNCES ADDITIONAL GRANTED BRAZILIAN PATENT FOR NEWEST VIVI BOX PRODUCT

Tempramed Technologies Ltd.'s Brazilian patent application No. BR 112021006921-6 has been formally granted by the Brazilian Patent Office.

The patent covers key aspects of the company's first multimedication storage box, Vivi Box, which Tempramed is planning to launch to market at the end of 2026. Once launched, it will add to the existing portfolio of four products being sold in market. There are also many commercial application opportunities with the Vivi Box, which the company has started exploring.

Without limiting the scope of the patent, it includes core elements of Tempramed's proprietary thermal insulation and smart monitoring architecture, such as:

• Continuous temperature protection during power interruptions or refrigerator temperature fluctuations for several medication devices and vials;
• Portable, all-day travel functionality for secure on-the-go cold storage;
• Smart content tracking with cloud-based data integration, supporting adherence and remote monitoring.

These capabilities position Vivi Box at the intersection of home health care, digital health and connected medical devices, supporting Tempramed's strategy to expand beyond single-injection protection into scalable, multiformat medication management solutions.

"The grant of our Brazilian patent marks another important step in executing Tempramed's global intellectual property strategy and reinforces our commitment to addressing large, high-growth health care markets," said Ron Nagar, chief executive officer of Tempramed. "Brazil represents one of the largest diabetes markets globally, with millions of patients relying on temperature-sensitive medications daily. Securing protection in this region strengthens our ability to commercialize Vivi Box and deliver meaningful value to patients, health care providers and partners across Latin America.

"As we continue to expand our global footprint, protecting our core innovations remains central to our strategy. This milestone enhances our competitive positioning and supports our long-term objective of becoming a global leader in temperature-controlled medication management."

The patent grant builds on Tempramed's growing portfolio of issued patents across key international jurisdictions, including recent grants in Asia. Together, these milestones support the company's multiyear strategy to scale globally, introduce new product categories and expand partnerships across health care systems, pharmacy networks and medical device ecosystems.

With a strong foundation of patented, Food and Drug Administration-registered technologies and increasing validation from clinicians and distribution partners worldwide, including validation of its return on investment model for insurance payers as verified by hundreds of clinicians recommending Tempramed's Vivi Cap to patients through FrontRowMD, Tempramed continues to advance its mission of ensuring the safety, efficacy and accessibility of life-saving medications.

About Tempramed Technologies Ltd.

Tempramed is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered, thermal insulation devices that work 24-seven without batteries or external power. With a product line already in market including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed will continue to expand globally offering a solution for medication protection and adherence.

We seek Safe Harbor.